Walvax BioTech (300142)

Currency in CNY
11.88
-0.06(-0.50%)
Closed·
Earnings results expected today
300142 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.7611.96
52 wk Range
9.8514.65
Key Statistics
Bid/Ask
11.88 / 11.89
Prev. Close
11.94
Open
11.9
Day's Range
11.76-11.96
52 wk Range
9.85-14.65
Volume
25.77M
Average Volume (3m)
45.48M
1-Year Change
16.7155%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300142 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.00
Downside
-32.66%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Walvax BioTech News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.

Employees
1981
Market
China

Compare 300142 to Peers and Sector

Metrics to compare
300142
Peers
Sector
Relationship
P/E Ratio
107.4x42.2x−0.4x
PEG Ratio
4.30−0.970.00
Price/Book
2.2x2.2x2.6x
Price / LTM Sales
7.9x7.1x3.2x
Upside (Analyst Target)
−33.0%28.4%46.7%
Fair Value Upside
Unlock8.0%7.6%Unlock

Analyst Ratings

0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Strong Sell

Analysts 12-Month Price Target:

Average 8.00
(-32.66% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Sell8.00-32.66%7.00MaintainMar 31, 2026
Goldman Sachs
Sell8.00-32.66%9.00MaintainAug 27, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.11%
Dividend Yield
0.33%
Industry Median 1.54%
Annualized payout
0.04
Paid unevenly
5-Years Growth
+17.23%
Growth Streak

Earnings

Latest Release
Mar 28, 2026
EPS / Forecast
0.01 / 0.04
Revenue / Forecast
699.43M / 772.87M
EPS Revisions
Last 90 days

300142 Income Statement

FAQ

What Is the Walvax BioTech (300142) Stock Price Today?

The Walvax BioTech stock price today is 11.88 CNY.

What Stock Exchange Does Walvax BioTech Trade On?

Walvax BioTech is listed and trades on the Shenzhen Stock Exchange.

What Is the Stock Symbol for Walvax BioTech?

The stock symbol for Walvax BioTech is "300142."

Does Walvax BioTech Pay Dividends? What’s The Current Dividend Yield?

The Walvax BioTech dividend yield is 0.33%.

What Is the Walvax BioTech Market Cap?

As of today, Walvax BioTech market cap is 18.98B CNY.

What Is Walvax BioTech's Earnings Per Share (TTM)?

The Walvax BioTech EPS (TTM) is 0.11.

When Is the Next Walvax BioTech Earnings Date?

Walvax BioTech will release its next earnings report on Apr 24, 2026.

From a Technical Analysis Perspective, Is 300142 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Walvax BioTech Stock Split?

Walvax BioTech has split 5 times.

How Many Employees Does Walvax BioTech Have?

Walvax BioTech has 1981 employees.

What is the current trading status of Walvax BioTech (300142)?

As of Apr 24, 2026, Walvax BioTech (300142) is trading at a price of 11.88 CNY, with a previous close of 11.94 CNY. The stock has fluctuated within a day range of 11.76 CNY to 11.96 CNY, while its 52-week range spans from 9.85 CNY to 14.65 CNY.

What Is Walvax BioTech (300142) Price Target According to Analysts?

The average 12-month price target for Walvax BioTech is 8.00 CNY, with a high estimate of 8 CNY and a low estimate of 8 CNY. 0 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Sell. The stock has an -32.66% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.